XML 115 R74.htm IDEA: XBRL DOCUMENT
v3.20.2

Commitments and Contingencies (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K) | 12 Months Ended
--- | ---
Dec. 31, 2019
Brooklyn Immunotherapeutics, LLC [Member] |
Schedule of Future Commitments of Operating Lease | Future commitments under the Successor’s operating lease are as follows:
For the Years Ending December 31, |  | Amount |
2020 |  | $ | 553,189 |
2021 |  |  | 571,470 |
2022 |  |  | 588,918 |
2023 |  |  | 606,864 |
2024 |  |  | 624,172 |
Thereafter |  |  | 747,656 |
|  | $ | 3,692,269 |

X
- Definition Tabular disclosure of components of income from operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 30 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 6A -URI http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306 + Details
Name: | us-gaap_OperatingLeaseLeaseIncomeTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |